Participant flow20

How many started, completed or left each group, period by period.

1 to 20 of 20

Period	Milestone	Group	Participants
Overall Study	STARTED	Standard Dose Imatinib A	75
Overall Study	STARTED	High Dose Imatinib	78
Overall Study	STARTED	Dasatinib	126
Overall Study	STARTED	Standard Dose Imatinib B	127
Overall Study	Eligible	Standard Dose Imatinib A	73
Overall Study	Eligible	High Dose Imatinib	73
Overall Study	Eligible	Dasatinib	123
Overall Study	Eligible	Standard Dose Imatinib B	125
Overall Study	Eligible and Treated	Standard Dose Imatinib A	72
Overall Study	Eligible and Treated	High Dose Imatinib	73
Overall Study	Eligible and Treated	Dasatinib	123
Overall Study	Eligible and Treated	Standard Dose Imatinib B	123
Overall Study	COMPLETED	Standard Dose Imatinib A	37
Overall Study	COMPLETED	High Dose Imatinib	52
Overall Study	COMPLETED	Dasatinib	6
Overall Study	COMPLETED	Standard Dose Imatinib B	17
Overall Study	NOT COMPLETED	Standard Dose Imatinib A	38
Overall Study	NOT COMPLETED	High Dose Imatinib	26
Overall Study	NOT COMPLETED	Dasatinib	120
Overall Study	NOT COMPLETED	Standard Dose Imatinib B	110

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00070499/flow